Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 14Thoracic 2Dermatologic 2Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Hodgkin Disease 47Lymphoma 22Lymphoma, Non-Hodgkin 18Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 12Melanoma 9Lymphoma, B-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Lymphoma, Follicular 7Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Carcinoma, Renal Cell 5Burkitt Lymphoma 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Nivolumab × Lymphoid × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡